Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma.
Report of a case of orbital inflammation after the use of zoledronic acid for metastasized prostate cancer.
Dept. of Ophthalmology, Virga Jesse Ziekenhuis, Hasselt, Belgium. guymissotten@jessazh.be
G
G
Missotten
Y
Y
Verheezen
D000368:Aged; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D003232:Conjunctivitis, Acute Hemorrhagic / Q000139:chemically induced; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D007249:Inflammation / Q000139:chemically induced; D008297:Male; D016609:Neoplasms, Second Primary / Q000188:drug therapy*; D009455:Neurofibroma / Q000150:complications / Q000601:surgery; D009916:Orbital Diseases / Q000139:chemically induced*; D009918:Orbital Neoplasms / Q000150:complications / Q000601:surgery; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid